AMENDMENTS TO THE CLAIMS

IN THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application.

Please amend the claims as follows:

1. (Previously Presented) A compound of Formula (I):



(I)

wherein

G_1 is $(CH_2)_k$, where k is 1 to 3;

G_2 is

a) hydrogen

b) - C_{1-6} alkyl;

c) –aryl;

d) –C_{1-6} alkylaryl;

e)



where R_5 and R_6 are independently selected from the group consisting of

i) –H;

ii) -C_{1-6} alkyl;

iii) –aryl;

iv) -C_{1-6} alkylaryl;

v) -C(O)-O-C_{1-6} alkyl;

vi) -C(O)-O-C_{1-6} alkylaryl;

vii) -C(O)-O-C_{1-6} alkylcycloalkylaryl;

viii) -C(O)-NH-C_{1-6} alkyl;

ix) -C(O)-NH-C_{1-6} alkylaryl;

x) -SO_2-C_{1-6} alkyl;

xi) -SO_2-C_{1-6} alkylaryl;

xii) -SO_2-aryl;

xiii) -SO_2-NH-C_{1-6} alkyl;

xiv) -SO_2-NH-C_{1-6} alkylaryl;

xv) 

;

xvi) -C(O)-C_{1-6} alkyl; and

xvii) -C(O)-C_{1-6} alkylaryl; or

f) a group of the formula



,


,


,


, or


;

wherein

R_9, R_{10}, and R_{11} are independently selected from the group consisting of

i) -hydrogen;

ii) -C_{1-6} alkyl;

iii) –aryl;

iv) -C_{1-6} alkylaryl;

v) -C(O)-O-C_{1-6} alkyl;

vi) -C(O)-O-C_{1-6} alkylaryl;

vii) -C(O)-NH-C_{1-6} alkyl;

viii) -C(O)-NH-C_{1-6} alkylaryl;

ix) -SO_2-C_{1-6} alkyl;

x) -SO_2-C_{1-6} alkylaryl;

xi) -SO_2-aryl;

xii) -SO_2-NH-C_{1-6} alkyl;

xiii) -SO_2-NH-C_{1-6} alkylaryl;

xiv) -C(O)-C_{1-6} alkyl; and

xv) -C(O)-C_{1-6} alkylaryl; or

R_{10} and R_{11} are taken together to constitute a fused cycloalkyl, fused heterocyclyl, or fused aryl ring containing the atoms to which R_{10} and R_{11} are bonded;

R_1 is

a) hydrogen;
b) -C_{1-6} alkyl;
c) –aryl; or
d) -C_{1-6} alkylaryl;

R_2 is

a) -C_{1-6} alkyl;
b) –aryl;
c) -C_{1-6} alkylaryl; or
d) a group of the formula



wherein m and n are independently selected from 1, 2, 3, or 4; X is a direct bond, CH_2-, -O-, -S-, -S(O_2)-, -C(O)-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -$NHSO_2$-, -SO_2N(H)-, -C(O)-O-, -O-C(O)-, -$NHSO_2NH$-,



$-Q_1-$ is C_{1-6} alkylene, C_{2-6} alkenylene, or C_{2-6} alkynylene;

R_3 is

a) hydrogen;

b) $-C_{1-6}$ alkyl;

c) $-C_{1-6}$ alkylaryl; or

d) $-C_{1-6}$ alkoxyaryl;

R_4 is

a) 
;

b) 
; or

c) 
;

wherein L is $-CH_2-$, -O-, -N(H)-, -S-, SO_2-, -CON(H)-, -NHC(O)-, -NHCON(H)-, $-NHSO_2-$, $-SO_2N(H)-$, -C(O)-O-, $-NHSO_2NH-$, -O-CO-,



and

R_{36} and R_{37} are independently selected from the group consisting of hydrogen, aryl, C_1-C_6 alkyl, C_1-C_6 alkylaryl, C_1-C_6 alkoxy, and C_1-C_6 alkoxyaryl

R_{12} and R_{13} are independently selected from the group consisting of hydrogen, C_1-C_6 alkyl, C_1-C_6 alkylaryl, and aryl;

R_7 and R_8 are independently selected from the group consisting of hydrogen, C_1-C_6 alkyl, C_1-C_6 alkylaryl, and aryl; or R_7 and R_8 are taken together to form a ring having the formula $-(CH_2)_{o'}-Z'-(CH_2)_{p'}-$ bonded to the atoms to which R_7 and R_8 are attached, wherein o' and p' are, independently, 1, 2, 3, or 4; Z' is a direct bond, $-CH_2-$, -O-, -S-, $-S(O_2)-$, -C(O)-, -CON(H)-, -NHC(O)-, -NHCON(H)-, $-NHSO_2-$, $-SO_2N(H)-$, -C(O)-O-, -O-C(O)-, $-NHSO_2NH-$,



R_{40} and R_{41} are independently selected from the group consisting of hydrogen, aryl, C_1-C_6 alkyl, and C_1-C_6 alkylaryl; and

wherein

the aryl and/or alkyl group(s) in R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_9, R_{10}, R_{11}, R_{12}, and R_{13} may be optionally substituted 1-4 times with a substituent group, wherein said substituent group(s) or the term substituted refers to groups:

a) -H;

b) -Y-C_{1-6} alkyl;
-Y-aryl;
-Y-C_{-1-6} alkylaryl;
-Y-C_{1-6}-alkyl-$NR_{14}R_{15}$;
-Y-C_{1-6}-alkyl-W-R_{16};

wherein Y and W are independently selected from the group consisting of -CH_2-, -O-, -N(H), -S-, SO_2-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -$NHSO_2$-, -SO_2N(H)-, -C(O)-O-, -$NHSO_2$NH-, -O-CO-,



R_{16}, R_{17}, and R_{18} are independently selected from the group consisting of hydrogen, aryl, C_1-C_6 alkyl, C_1-C_6 alkylaryl, C_1-C_6 alkoxy, and C_1-C_6 alkoxyaryl; and

c) halogen, hydroxyl, cyano, carbamoyl, and carboxyl; and

R_{14} and R_{15} are independently selected from the group consisting of hydrogen, aryl, C_1-C_6 alkyl, and C_1-C_6 alkylaryl; or

R_{14} and R_{15} are taken together to form a ring having the formula $-(CH_2)_o-Z-(CH_2)_p-$ bonded to the nitrogen atom to which R_{14} and R_{15} are attached, wherein o and p are, independently, 1, 2, 3, or 4; Z is a direct bond, $-CH_2-$, -O-, -S-, $-S(O_2)-$, -C(O)-, -CON(H)-, -NHC(O)-, -NHCON(H)-, $-NHSO_2-$, $-SO_2N(H)-$, -C(O)-O-, -O-C(O)-, $-NHSO_2NH-$,



and

R_{19} and R_{20} are independently selected from the group consisting of hydrogen, aryl, C_1-C_6 alkyl, and C_1-C_6 alkylaryl,

or a pharmaceutically acceptable salt thereof.

2. (Canceled)

3. (Canceled)

4. (Previously Presented) The compound of claim 1, represented by Formula (Ic):



(Ic)

wherein,

R_1 is hydrogen, or C_{1-3} alkylaryl wherein the aryl is substituted with $-Y-C_{1-6}$ alkylaryl;

R_2 is C_{1-3} alkylaryl wherein the aryl is substituted with -Y-C_{1-6} alkylaryl,

wherein Y is $-CH_2-$, -O-, -N(H), -S-, SO_2-, -CON(H)-, -NHC(O)-, -NHCON(H)-, $-NHSO_2-$, $-SO_2N(H)-$, -C(O)-O-, $-NHSO_2NH-$, -O-CO-,



R_{17}, and R_{18} independently is hydrogen, aryl, C_1-C_6 alkyl, C_1-C_6 alkylaryl, C_1-C_6 alkoxy, or C_1-C_6 alkoxyaryl,

or a pharmaceutically acceptable salt thereof.

5. (Previously Presented) The compound of claim 1, represented by Formula (Id):



(Id)

wherein,

R_1 is hydrogen, or C_{1-3} alkylaryl wherein the aryl is substituted with -Y-C_{1-6} alkylaryl;

R_2 is C_{1-3} alkylaryl wherein the aryl is substituted with -Y-C_{1-6} alkylaryl;

wherein Y is $-CH_2-$, -O-, -N(H), -S-, SO_2-, -CON(H)-, -NHC(O)-, -NHCON(H)-, $-NHSO_2-$, $-SO_2N(H)-$, -C(O)-O-, $-NHSO_2NH-$, -O-CO-,



R_{17}, and R_{18} independently is hydrogen, aryl, C_1-C_6 alkyl, C_1-C_6 alkylaryl, C_1-C_6 alkoxy, or C_1-C_6 alkoxyaryl;

R_3 is hydrogen or –L-C_{1-6}-alkyl-N(alkyl)$_2$;

R_{14} and R_{15} are alkyl; and

wherein L is -CH_2-, -O-, -N(H)-, -S-, SO_2-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -$NHSO_2$-, -SO_2N(H)-, -C(O)-O-, -$NHSO_2$NH-, -O-CO-,



R_{35}, R_{36}, and R_{37} independently are hydrogen, aryl, C_1-C_6 alkyl, C_1-C_6 alkylaryl, C_1-C_6 alkoxy, or C_1-C_6 alkoxyaryl,

or a pharmaceutically acceptable salt thereof.

6. (Canceled)

7. (Canceled)

8. (Canceled)

9. (Canceled)

10. (Canceled)

11. (Previously Presented) The compound of claim 1, wherein the compound is 3-(4-Benzyloxyphenyl)propionic Acid 2,4-Di-(3-Diethylamino-1-propoxy)aniline Amide or a pharmaceutically acceptable salt thereof.

12. (Previously Presented) The compound of claim 61, wherein the compound is 3-(3-Tert-butoxyphenyl)-3-(9-fluorenylmethoxycarbonylamino)propionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide or a pharmaceutically acceptable salt thereof.

13. (Previously Presented) The compound of claim 62, wherein the compound is 3-(3-Tert-butoxyphenyl)-3-aminopropionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide or a pharmaceutically acceptable salt thereof.

Claims 14 - 17. (Canceled)

18. (Previously Presented) The compound of claim 61, wherein the compound is 3-(4-Tert-butoxyphenyl)-3-(9-fluorenylmethoxycarbonylamino)propionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide or a pharmaceutically acceptable salt thereof.

19. (Previously Presented) The compound of claim 62, wherein the compound is 3-amino-3-(4-tert-butoxyphenyl)propionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide or a pharmaceutically acceptable salt thereof.

20. (Previously Presented) The compound of claim 61, wherein the compound is 3-(9-fluorenylmethoxycarbonylamino)-3-(2-tert-butoxyphenyl)propionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide or a pharmaceutically acceptable salt thereof.

21. (Previously Presented) The compound of claim 62, wherein the compound is 3-amino-3-(2-tert-butoxyphenyl)propionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide or a pharmaceutically acceptable salt thereof.

22. (Previously Presented) The compound of claim 62, wherein the compound is 3-Isopropylamino-3-(3-tert-butoxyphenyl)propionic Acid 2,4-Di-(3-diethylaminopropoxy)aniline Amide or a pharmaceutically acceptable salt thereof.

Claims 23-40. (Canceled)

41. (Previously Presented) A pharmaceutical composition comprising the compound of Formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, excipients, or diluents.

42. (Original) The pharmaceutical composition of claim 41, in the form of an oral dosage or parenteral dosage unit.

43. (Previously Presented) The pharmaceutical composition of claim 41, wherein the pharmaceutical composition is suitable for administration of said compound as a dose in a range from about 0.01 to 500 mg/kg of body weight per day.

44. (Previously Presented) The pharmaceutical composition of claim 41, wherein the pharmaceutical composition is suitable for administration of said compound as a dose in a range from about 0.1 to 200 mg/kg of body weight per day.

45. (Previously Presented) The pharmaceutical composition of claim 41, wherein the pharmaceutical composition is suitable for administratoin of said compound as a dose in a range from about 0.1 to 100 mg/kg of body weight per day.

46. (Original) The pharmaceutical composition of claim 41, further comprising one or more therapeutic agents selected from the group consisting of alkylating agents, antimetabolites, plant alkaloids, antibiotics, hormones, biologic response modifiers,

analgesics, NSAIDs, DMARDs, glucocorticoids, sulfonylureas, biguanides, insulin, cholinesterase inhibitors, antipsychotics, antidepressants, and anticonvulsants.

47. (Previously Presented) A method for the inhibition of the interaction of RAGE with its physiological ligands, which comprises administering to a subject in need thereof, at least one compound of Formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt thereof.

48. (Original) The method of claim 47, wherein the ligand(s) is(are) selected from advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin.

49. (Currently Amended) A method for inhibiting RAGE in a subject having a disease state selected from the group consisting of acute and chronic inflammation, symptoms of diabetes, vascular permeability, nephropathy, atherosclerosis, retinopathy, Alzheimer's disease, erectile dysfunction, and tumor invasion and/or metastasis, which comprises administering to a subject in need thereof a therapeutically effective amount of at least one compound of Formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt thereof.

50. (Currently Amended) A method of inhibiting RAGE in a human having a RAGE mediated human ~~diseases~~ disease comprising administration to a human in need thereof a therapeutically effective amount of a compound of Formula (I) as claimed in claim 1, wherein a therapeutically effective amount comprises sufficient compound to at least partially inhibit the binding of a ligand to the RAGE receptor or a pharmaceutically acceptable salt thereof.

51. (Original) The method of claim 50, further comprising administering to a subject in need thereof at least one adjuvant and/or additional therapeutic agent(s).

52. (Original) A method of claim 51, wherein therapeutic agents selected from the group consisting of alkylating agents, antimetabolites, plant alkaloids, antibiotics, hormones, biologic response modifiers, analgesics, NSAIDs, DMARDs, glucocorticoids, sulfonylureas, biguanides, insulin, cholinesterase inhibitors, antipsychotics, antidepressants, and anticonvulsants.

53. (Previously Presented) The method of claim 50, wherein the RAGE mediated human disease comprises acute and/or chronic inflammation.

54. (Previously Presented) The method of claim 50, wherein the RAGE mediated human disease comprises vascular permeability.

55. (Previously Presented) The method of claim 50, wherein the RAGE mediated human disease comprises nephropathy.

56. (Previously Presented) The method of claim 50, wherein the RAGE mediated human disease comprises atherosclerosis.

57. (Previously Presented) The method of claim 50, wherein the RAGE mediated human disease comprises retinopathy.

58. (Previously Presented) The method of claim 50, wherein the RAGE mediated human disease comprises Alzheimer's disease.

59. (Previously Presented) The method of claim 50, wherein the RAGE mediated human disease comprises erectile dysfunction.

60. (Previously Presented) The method of claim 50, wherein the RAGE mediated human disease comprises tumor invasion and/or metastasis.

61. (Previously Presented) The compound of Formula (I) in claim 1 or a pharmaceutically acceptable salt thereof, wherein

G_1 is $-CH_2-$

G_2 is



wherein

R_5 and R_6 are independently selected from the group consisting of

i) –H;
ii) $-C_{1-6}$ alkyl;
iii) –aryl;
iv) $-C_{1-6}$ alkylaryl;
v) $-C(O)-O-C_{1-6}$ alkyl;
vi) $-C(O)-O-C_{1-6}$ alkylaryl;
vii) $-C(O)-O-C_{1-6}$ alkylcycloalkylaryl;
viii) $-C(O)-NH-C_{1-6}$ alkyl;
ix) $-C(O)-NH-C_{1-6}$ alkylaryl;
x) $-SO_2-C_{1-6}$ alkyl;
xi) $-SO_2-C_{1-6}$ alkylaryl;
xii) $-SO_2$-aryl;
xiii) $-SO_2-NH-C_{1-6}$ alkyl;
xiv) $-SO_2-NH-C_{1-6}$ alkylaryl;

xv) 

;

xvi) -C(O)-C_{1-6} alkyl; or

xvii) -C(O)-C_{1-6} alkylaryl;

R_1 is

a) hydrogen;

b) -C_{1-6} alkyl;

c) -aryl; or

d) -C_{1-6} alkylaryl;

R_2 is

a) -C_{1-6} alkyl;

b) –aryl;

c) -C_{1-6} alkylaryl; or

d) a group of the formula



wherein m and n are independently selected from 1, 2, 3, or 4; X is a direct bond, CH_2-, -O-, -S-, -S(O_2)-, -C(O)-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -$NHSO_2$-, -SO_2N(H)-, -C(O)-O-, -O-C(O)-, -$NHSO_2$NH-,



$-Q_1-$ is C_{1-6} alkylene, C_{2-6} alkenylene, or C_{2-6} alkynylene;

R_3 is

a) hydrogen;

b) $-C_{1-6}$ alkyl;

c) $-C_{1-6}$ alkylaryl; or

d) $-C_{1-6}$ alkoxyaryl;; and

R_4 is

a)



b)



; or

c)



wherein L is $-CH_2-$, -O-, -N(H)-, -S-, SO_2-, -CON(H)-, -NHC(O)-, -NHCON(H)-, $-NHSO_2-$, $-SO_2N(H)-$, -C(O)-O-, $-NHSO_2NH-$, -O-CO-,



R_{36} and R_{37} are independently selected from the group consisting of hydrogen, aryl, C_1-C_6 alkyl, C_1-C_6 alkylaryl, C_1-C_6 alkoxy, and C_1-C_6 alkoxyaryl;

R_{12} and R_{13} are independently selected from the group consisting of hydrogen, C_1-C_6 alkyl, C_1-C_6 alkylaryl, and aryl;

R_7 and R_8 are independently selected from the group consisting of hydrogen, C_1-C_6 alkyl, C_1-C_6 alkylaryl, and aryl; or R_7 and R_8 are taken together to form a ring having the formula $-(CH_2)_{o'}-Z'-(CH_2)_{p'}-$ bonded to the atoms to which R_7 and R_8 are attached, wherein o' and p' are, independently, 1, 2, 3, or 4; Z' is a direct bond, $-CH_2-$, -O-, -S-, $-S(O_2)-$, -C(O)-, -CON(H)-, -NHC(O)-, -NHCON(H)-, $-NHSO_2-$, $-SO_2N(H)-$, -C(O)-O-, -O-C(O)-, $-NHSO_2NH-$,



and

R_{40} and R_{41} are independently selected from the group consisting of hydrogen, aryl, C_1-C_6 alkyl, and C_1-C_6 alkylaryl; and

wherein

the aryl and/or alkyl group(s) in R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_{12} and R_{13} may be optionally substituted 1-4 times with a substituent group, wherein said substituent group(s) or the term substituted refers to groups:

a) -H;

b) -Y-C_{1-6} alkyl;
-Y-aryl;
-Y-C_{-1-6} alkylaryl;
-Y-C_{1-6}-alkyl-$NR_{14}R_{15}$;
-Y-C_{1-6}-alkyl-W-R_{16};

wherein Y and W are independently selected from the group consisting of -CH_2-, -O-, -N(H), -S-, SO_2-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -$NHSO_2$-, -$SO_2N(H)$-, -C(O)-O-, -$NHSO_2NH$-, -O-CO-,



R_{16}, R_{17}, and R_{18} are independently selected from the group consisting of hydrogen, aryl, C_1-C_6 alkyl, C_1-C_6 alkylaryl, C_1-C_6 alkoxy, and C_1-C_6 alkoxyaryl; and

c) halogen, hydroxyl, cyano, carbamoyl, and carboxyl; and

R_{14} and R_{15} are independently selected from the group consisting of hydrogen, aryl, C_1-C_6 alkyl, and C_1-C_6 alkylaryl; or

R_{14} and R_{15} are taken together to form a ring having the formula $-(CH_2)_o-Z-(CH_2)_p-$ bonded to the nitrogen atom to which R_{14} and R_{15} are attached, wherein o and p are, independently, 1, 2, 3, or 4; Z is a direct bond, $-CH_2-$, -O-, -S-, $-S(O_2)-$, -C(O)-, -CON(H)-, -NHC(O)-, -NHCON(H)-, $-NHSO_2-$, $-SO_2N(H)-$, -C(O)-O-, -O-C(O)-, $-NHSO_2NH-$,



and

R_{19} and R_{20} are independently selected from the group consisting of hydrogen, aryl, C_1-C_6 alkyl, and C_1-C_6 alkylaryl.

62. (Previously Presented) The compound of Formula (I) in claim 61 or a pharmaceutically acceptable salt thereof,

wherein

G_1 is $-CH_2-$

G_2 is



wherein

R_5 is –H; and

R_6 is

i) –H;

ii) $-C_{1-6}$ alkyl; or

iii) $-C(O)-O-C_{1-6}$ alkylcycloalkylaryl;

R_1 is –H;

R_2 is



;

R_3 is –H; and

R_4 is

a)



;

b)



; or

c)



;

wherein L is $-CH_2-$, -O-, -N(H)-, -S-, SO_2-, -CON(H)-, -NHC(O)-, -NHCON(H)-, $-NHSO_2-$, $-SO_2N(H)-$, -C(O)-O-, $-NHSO_2NH-$, -O-CO-,



;

R_{36} and R_{37} are independently selected from the group consisting of hydrogen, aryl, C_1-C_6 alkyl, C_1-C_6 alkylaryl, C_1-C_6 alkoxy, and C_1-C_6 alkoxyaryl;

and wherein

the aryl and/or alkyl group(s) in R_1, R_2, R_3, R_4, R_5, R_6, R_7, R_8, R_{12} and R_{13} may be optionally substituted 1-4 times with a substituent group, wherein said substituent group(s) or the term substituted refers to groups:

a) -H;

b) -Y-C_{1-6} alkyl;
-Y-aryl;
-Y-C_{-1-6} alkylaryl;
-Y-C_{1-6}-alkyl-$NR_{14}R_{15}$;
-Y-C_{1-6}-alkyl-W-R_{16};

wherein Y and W are independentlyselected from the group consisting of -CH_2-, -O-, -N(H), -S-, SO_2-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -$NHSO_2$-, -$SO_2N(H)$-, -C(O)-O-, -$NHSO_2NH$-, -O-CO-,



R_{16}, R_{17}, and R_{18} are independently selected from the group consisting of hydrogen, aryl, C_1-C_6 alkyl, C_1-C_6 alkylaryl, C_1-C_6 alkoxy, and C_1-C_6 alkoxyaryl; and

c) halogen, hydroxyl, cyano, carbamoyl, or carboxyl; and

R_{14} and R_{15} are independently selected from the group consisting of hydrogen, aryl, C_1-C_6 alkyl, and C_1-C_6 alkylaryl; or

R_{14} and R_{15} are taken together to form a ring having the formula $-(CH_2)_o-Z-(CH_2)_p-$ bonded to the nitrogen atom to which R_{14} and R_{15} are attached, wherein o and p are, independently, 1, 2, 3, or 4; Z is a direct bond, $-CH_2-$, -O-, -S-, $-S(O_2)-$, -C(O)-, -CON(H)-, -NHC(O)-, $-NHCON(H)-$, $-NHSO_2-$, $-SO_2N(H)-$, -C(O)-O-, -O-C(O)-, $-NHSO_2NH-$,



and

R_{19} and R_{20} are independently selected from the group consisting of hydrogen, aryl, C_1-C_6 alkyl, and C_1-C_6 alkylaryl.

63. (Previously Presented) A pharmaceutical composition comprising the compound of Formula (I) as claimed in claim 4 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, excipients, or diluents.

64. (Previously Presented) A pharmaceutical composition comprising the compound of Formula (I) as claimed in claim 5 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, excipients, or diluents.

65. (Previously Presented) A pharmaceutical composition comprising the compound of Formula (I) as claimed in claim 11 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, excipients, or diluents.

66. (Previously Presented) A pharmaceutical composition comprising the compound of Formula (I) as claimed in claim 12 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, excipients, or diluents.

67. (Previously Presented) A pharmaceutical composition comprising the compound of Formula (I) as claimed in claim 13 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, excipients, or diluents.

68. (Previously Presented) A pharmaceutical composition comprising the compound of Formula (I) as claimed in claim 18 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, excipients, or diluents.

69. (Previously Presented) A pharmaceutical composition comprising the compound of Formula (I) as claimed in claim 19 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, excipients, or diluents.

70. (Previously Presented) A pharmaceutical composition comprising the compound of Formula (I) as claimed in claim 20 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, excipients, or diluents.

71. (Previously Presented) A pharmaceutical composition comprising the compound of Formula (I) as claimed in claim 21 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, excipients, or diluents.

72. (Previously Presented) A pharmaceutical composition comprising the compound of Formula (I) as claimed in claim 22 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, excipients, or diluents.